Patent · US Active

Compounds and methods for the targeted degradation of androgen receptor

US11964945B2 · kind B2 · utility

1Cited by
22References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 29, 2020
Grant dateApr 23, 2024
Priority date
Expiry dateMay 29, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D401/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.